<div id="readability-page-1"><p>Kodiak Sciences Inc. (NASDAQ:KOD - Get Free Report) gapped up prior to trading on Monday following insider buying activity. The stock had previously closed at $26.00, but opened at $27.95. Kodiak Sciences shares last traded at $28.2410, with a volume of 141,605 shares trading hands.</p><div><p><span></span><span>Get <strong>Kodiak Sciences</strong> alerts:</span></p></div><p>Specifically,  Director Bros. Advisors Lp Baker bought 2,608,696 shares of the stock in a transaction on Thursday, December 18th. The shares were purchased at an average price of $23.00 per share, with a total value of $60,000,008.00. Following the acquisition, the director directly owned 18,358,772 shares of the company's stock, valued at $422,251,756. This represents a 16.56% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. </p><h2>Analysts Set New Price Targets</h2><p>Several brokerages have issued reports on KOD. Weiss Ratings  reaffirmed a &#34;sell (e+)&#34; rating on shares of Kodiak Sciences in a research report on Wednesday, October 8th. Lifesci Capital initiated coverage on shares of Kodiak Sciences in a research report on Thursday, October 23rd. They issued an &#34;outperform&#34; rating and a $40.00 target price for the company. JPMorgan Chase &amp; Co. raised Kodiak Sciences from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating and increased their price target for the company from $15.00 to $24.00 in a research report on Friday, October 24th. Chardan Capital  restated a &#34;neutral&#34; rating and set a $14.00 target price on shares of Kodiak Sciences in a research report on Monday, November 17th. Finally, Wall Street Zen downgraded Kodiak Sciences from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, October 11th. Four equities research analysts have rated the stock with a Buy rating, two have issued  a Hold rating and one  has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of &#34;Hold&#34; and a consensus price target of $22.67.</p><p><b>Check Out Our Latest Analysis on KOD</b></p><h2>Kodiak Sciences Stock Performance</h2><p>The company has a market cap of $1.46 billion, a price-to-earnings ratio of -6.85 and a beta of 2.68. The company has a fifty day moving average of $20.38 and a two-hundred day moving average of $12.43. </p><p>Kodiak Sciences (NASDAQ:KOD - Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported ($1.16) earnings per share for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.09).  Equities analysts expect that  Kodiak Sciences Inc. will post -3.45 EPS for the current fiscal year. </p><h2>Institutional Trading of Kodiak Sciences</h2><p>Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Headlands Technologies LLC boosted its position in shares of  Kodiak Sciences by 256.4% during the 2nd quarter. Headlands Technologies LLC now owns 8,083 shares of the company's stock worth $30,000 after purchasing an additional 5,815 shares in the last quarter.  Walleye Capital LLC acquired a new stake in shares of  Kodiak Sciences during the 1st quarter worth approximately $49,000.  Vanguard Personalized Indexing Management LLC lifted its holdings in  Kodiak Sciences by 21.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,070 shares of the company's stock worth $56,000 after purchasing an additional 2,691 shares during the period.  Russell Investments Group Ltd. grew its holdings in shares of  Kodiak Sciences by 729.9% in the 1st quarter. Russell Investments Group Ltd. now owns 21,039 shares of the company's stock worth $59,000 after acquiring an additional 18,504 shares during the last quarter.  Finally, Dynamic Technology Lab Private Ltd acquired a new position in  Kodiak Sciences during the first quarter valued at $94,000. 89.06% of the stock is owned by institutional investors and hedge funds. </p><h2>Kodiak Sciences Company Profile</h2> (Get Free Report)<p>Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company's proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak's research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.  </p><p>The lead product candidate in Kodiak's pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.</p><h2>See Also</h2><ul><li>Five stocks we like better than Kodiak Sciences</li><li>Wall Street Stock picker Names #1 Stock of 2026</li><li>Do not delete, read immediately</li><li>How Long Will $1M Last in Retirement?</li><li>Buy this $2 Gold Stock Before January 1, 2026</li><li>“$6.6 Trillion Of Customer Bank Deposits At Risk”</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Kodiak Sciences Right Now?</h2><p>Before you consider Kodiak Sciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.</p><p>While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Kodiak Sciences (NASDAQ:KOD) shares rose after insider buying activity. Director Bros. Advisors Lp Baker purchased 2,608,696 shares at $23.00 each, totaling $60 million. The stock opened at $27.95, up from the previous close of $26.00, and last traded at $28.2410. Analysts have mixed ratings on the stock, with a consensus rating of 'Hold' and a price target of $22.67. Kodiak Sciences focuses on therapies for retinal diseases, with its lead product candidate being KSI-301.</p>

Kodiak Sciences (NASDAQ:KOD) Shares Gap Up After Insider Buying Activity